Richter lifts 2026 targets as exchange rates mask near-12% underlying sales growth

Gedeon Richter has raised its 2026 targets after a first nine months in which exchange-rate movements cut sharply into the revenue it booked. Pharmaceutical sales for January to September came to HUF 686.5bn, up 2.6% on the prior-year period. Stripping out currency effects, the increase was 11.7%.

The company puts the translation effect at about nine points, which accounts for most of the gap between the two growth rates. Net profit for the period rose 7% to HUF 174.9bn. The figures were published on 10 November 2026.

Richter named three engines behind the underlying expansion: cariprazine, sold as Vraylar and Reagila; its biosimilars and contract development and manufacturing (CDMO) activities; and women's health, including Ryeqo and Lenzetto. The information available does not break out sales or growth rates for any of them.

For the full year, management now expects constant-currency revenue growth of more than 10% and growth in Clean EBIT in the high teens. The earlier guidance range was not available to CompePharma, so the size of the upgrade cannot be measured here. Nor does the material explain what pricing, reimbursement or regulatory factors sit behind the revised outlook.